Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and revenue outlook during the class period from February 8, 2024, to February 2, 2026 [1][3][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that PayPal's management misrepresented the company's projected revenue and growth, creating a false impression of stability and reliability in the face of macroeconomic challenges [3][6]. - Investors have until April 20, 2026, to file for lead plaintiff status in the class action [1][6]. Stock Performance - PayPal's stock price dropped by $10.63, or 20.3%, closing at $41.70 per share on February 3, 2026, following a surprise leadership change and disappointing earnings report that missed consensus estimates [4]. Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss their legal rights [2][6][9]. - Investors can choose to file for lead plaintiff status or remain as absent class members, with no cost associated with the legal representation [8].

Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for securities fraud, with the Rosen Law Firm representing investors who purchased securities between November 3, 2023, and March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the Class Period, Aldeyra made false and misleading statements regarding the clinical trials of its drug candidate reproxalap, leading to unreliable positive findings [5]. - Investors who purchased Aldeyra securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action must move the Court by May 29, 2026, to serve as lead plaintiff, representing other class members in the litigation [3]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4].

Core Viewpoint - Halper Sadeh LLC is investigating whether Olaplex Holdings, Inc. is obtaining a fair price for its shareholders in the proposed sale to Henkel AG & Co. KGaA at $2.06 per share [2][4]. Group 1: Investigation Details - The investigation focuses on whether Olaplex and its board violated federal securities laws and fiduciary duties by failing to secure the best price for shareholders, conducting a fair sales process, and disclosing all material information [4]. - Insiders may benefit financially from the transaction in ways not available to ordinary shareholders, raising concerns about potential conflicts of interest [1][4]. Group 2: Shareholder Rights - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options at no cost, with the firm operating on a contingent fee basis [2][3]. - The firm may seek increased consideration, additional disclosures, or other relief for shareholders [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Grocery Outlet Holding Corp. for allegedly misleading investors regarding the company's financial health and operational growth during the specified class period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Grocery Outlet securities between August 5, 2025, and March 4, 2026 [2][7]. - The case is registered in the United States District Court for the Northern District of California, under the title Jones v. Grocery Outlet Holding Corp., Case No. 3:26-cv-02291 [2]. - Investors have until May 15, 2026, to file for lead plaintiff status [2][7]. Group 2: Allegations - The complaint alleges that Grocery Outlet made materially false and misleading statements and failed to disclose critical facts about its business and operations [4]. - Specific allegations include that the company expanded too quickly, leading to unsustainable growth and necessitating significant store closures and asset write-downs [4]. - The lawsuit claims that the positive statements made by the company regarding its business prospects were materially misleading [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results for the fourth quarter and full fiscal year 2025, Grocery Outlet's stock price dropped by $2.45 per share, or 27.9%, closing at $6.34 per share on March 5, 2026 [5]. - The CEO acknowledged the need to close 36 locations due to the rapid expansion strategy, which was deemed a mistake [5]. Group 4: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options and legal rights [3][10]. - Investors can seek to be appointed as lead plaintiff representatives or choose to remain absent class members [9]. - The law firm operates on a contingency fee basis, meaning there is no cost to the investors unless they recover funds [13].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to alleged securities fraud, with a lead plaintiff deadline set for April 6, 2026, for investors who purchased American Depositary Shares (ADS) during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Mereo provided misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing adverse facts about the studies, which did not meet their primary endpoints [6]. Group 2: Investor Actions - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7].

Core Viewpoint - Investors have the opportunity to lead a class action lawsuit against Pinterest, Inc. for alleged securities fraud related to misleading statements about the company's advertising revenue and the impact of tariffs on its business [1][5]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is defined as from February 7, 2025, to February 12, 2026 [2]. - Investors who suffered losses during this period are encouraged to contact the Schall Law Firm before May 29, 2026 [2]. Group 2: Allegations Against Pinterest - The complaint alleges that Pinterest made false and misleading statements regarding its advertising revenue and the effects of tariffs on its business [5]. - The company reportedly downplayed the negative impact of tariffs on its advertising partners, leading to materially misleading public statements throughout the class period [5]. - As a result of these misleading statements, investors experienced damages when the truth about Pinterest's financial situation was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's investigational drug candidate reproxalap [2][4]. Group 1: Lawsuit Details - The class action lawsuit involves allegations that Aldeyra and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Aldeyra securities during the Class Period have until May 29, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: FDA Response and Stock Impact - On March 17, 2026, Aldeyra received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy [4]. - Following the announcement of the CRL, Aldeyra's stock price fell by $2.99 per share, or 70.69%, closing at $1.24 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Vital Farms, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by contacting Pomerantz LLP [1][2]. Financial Performance - Vital Farms reported annual revenue of $759.44 million for 2025, which was below its guidance of $775 million [4]. - The company reported earnings per share of $0.35, missing the consensus estimate of $0.39 [4]. - The implementation of an enterprise resource planning (ERP) system caused temporary disruptions in order and fulfillment levels, contributing to lower volume growth than expected [4]. Stock Market Reaction - Following the announcement of the financial results and ERP issues, Vital Farms' stock price fell by $2.68 per share, or 10.81%, closing at $22.11 per share on February 26, 2026 [5].

Core Viewpoint - A class action lawsuit has been filed against Lufax Holding Ltd. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Lufax and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors have until May 20, 2026, to request to be appointed as Lead Plaintiff if they purchased Lufax securities during the Class Period [2]. Group 2: Auditor Concerns - On January 27, 2025, Lufax announced plans to remove its auditor, PricewaterhouseCoopers (PwC), due to significant concerns regarding Lufax's financial disclosures, particularly the 2022 and 2023 Annual Reports [4]. - PwC's concerns led to the conclusion that its audit opinions for the 2022 and 2023 Annual Reports were no longer reliable [4]. - Following this announcement, Lufax's American Depositary Share price dropped nearly 22% over three trading sessions [4].

Core Viewpoint - Pomerantz LLP is investigating claims of securities fraud and unlawful business practices involving ChowChow Cloud International Holdings Ltd, following a significant stock price collapse attributed to market manipulation and a "pump-and-dump" scheme [1][3]. Group 1: Investigation and Allegations - The investigation by Pomerantz LLP is focused on whether ChowChow and its officers or directors engaged in fraudulent activities [1]. - A complaint has been filed regarding the sudden collapse of ChowChow's stock price on December 10, 2025, which included multiple trading halts by NYSE American due to volatility [3]. - Allegations suggest that ChowChow was used in a market manipulation scheme, where impersonators posed as financial advisors to promote the stock with unfounded claims, leading to a buying frenzy among retail investors [3]. Group 2: Stock Price Collapse Details - On December 10, 2025, ChowChow's stock price fell dramatically from $11.95 to $10.59 within minutes due to a surge of sell orders totaling approximately 360,000 shares [3]. - Trading was halted by NYSE American at 11:07 AM EST and resumed at approximately $1.00 per share, reflecting a significant loss for investors [3]. - The stock ultimately closed at $1.83 per share, marking a single-day loss of 84.3% [4].